27601594|t|Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
27601594|a|Purpose: Some forms of chemotherapy can enhance antitumor immunity through immunogenic cell death, resulting in increased T-cell activation and tumor infiltration. Such effects could potentially sensitize tumors to immunotherapies, including checkpoint blockade. We investigated whether platinum - and taxane -based chemotherapy for ovarian cancer induces immunologic changes consistent with this possibility. Experimental Design: Matched pre - and post - neoadjuvant chemotherapy tumor samples from 26 high-grade serous carcinoma (HGSC) patients were analyzed by immunohistochemistry (IHC) for a large panel of immune cells and associated factors. The prognostic significance of post - chemotherapy TIL patterns was assessed in an expanded cohort (n = 90).Results: Neoadjuvant chemotherapy was associated with increased densities of CD3 (+), CD8 (+), CD8 (+) TIA-1 (+), PD-1 (+) and CD20 (+) TIL. Other immune subsets and factors were unchanged, including CD79a (+) CD138 (+) plasma cells, CD68 (+) macrophages, and MHC class I on tumor cells. Immunosuppressive cell types were also unchanged, including FoxP3 (+) PD-1 (+) cells (putative regulatory T cells), IDO-1 (+) cells, and PD-L1 (+) cells (both macrophages and tumor cells). Hierarchical clustering revealed three response patterns: (i) TIL (high) tumors showed increases in multiple immune markers after chemotherapy; (ii) TIL (low) tumors underwent similar increases, achieving patterns indistinguishable from the first group; and (iii) TIL (negative) cases generally remained negative. Despite the dramatic increases seen in the first two patterns, post- chemotherapy TIL showed limited prognostic significance.Conclusions: Chemotherapy augments pre-existing TIL responses but fails to relieve major immune-suppressive mechanisms or confer significant prognostic benefit. Our findings provide rationale for multipronged approaches to immunotherapy tailored to the baseline features of the tumor microenvironment. Clin Cancer Res; 23(4); 925-34. Â©2016 AACR.
27601594	28	42	Ovarian Cancer	T038	UMLS:C0029925
27601594	72	101	Tumor-Infiltrating Lymphocyte	T017	UMLS:C0079722
27601594	102	110	Response	T038	UMLS:C0301909
27601594	142	155	Immunotherapy	T058	UMLS:C0278348
27601594	179	191	chemotherapy	T058	UMLS:C0392920
27601594	214	222	immunity	T038	UMLS:C0020964
27601594	243	253	cell death	T038	UMLS:C0007587
27601594	278	295	T-cell activation	T038	UMLS:C1155065
27601594	361	367	tumors	T038	UMLS:C0027651
27601594	371	386	immunotherapies	T058	UMLS:C0278348
27601594	398	417	checkpoint blockade	T038	UMLS:C1155873
27601594	443	451	platinum	T103	UMLS:C0032207
27601594	458	464	taxane	T103	UMLS:C0215136
27601594	472	484	chemotherapy	T058	UMLS:C0392920
27601594	489	503	ovarian cancer	T038	UMLS:C0029925
27601594	566	585	Experimental Design	T062	UMLS:C0015320
27601594	637	650	tumor samples	T017	UMLS:C0475358
27601594	659	686	high-grade serous carcinoma	T038	UMLS:C3839280
27601594	688	692	HGSC	T038	UMLS:C3839280
27601594	720	740	immunohistochemistry	T058	UMLS:C0021044
27601594	742	745	IHC	T058	UMLS:C0021044
27601594	768	780	immune cells	T017	UMLS:C0312740
27601594	843	855	chemotherapy	T058	UMLS:C0392920
27601594	856	859	TIL	T017	UMLS:C0079722
27601594	897	903	cohort	T098	UMLS:C0599755
27601594	990	993	CD3	T103	UMLS:C0108779
27601594	999	1002	CD8	T103	UMLS:C0085358
27601594	1008	1011	CD8	T103	UMLS:C0085358
27601594	1016	1021	TIA-1	T103	UMLS:C1429678
27601594	1027	1031	PD-1	T103	UMLS:C2986635
27601594	1040	1044	CD20	T103	UMLS:C0054946
27601594	1049	1052	TIL	T017	UMLS:C0079722
27601594	1113	1118	CD79a	T103	UMLS:C0286618
27601594	1123	1128	CD138	T103	UMLS:C1609943
27601594	1133	1145	plasma cells	T017	UMLS:C0032112
27601594	1147	1151	CD68	T103	UMLS:C0108799
27601594	1156	1167	macrophages	T017	UMLS:C0024432
27601594	1173	1184	MHC class I	T103	UMLS:C0019629
27601594	1188	1199	tumor cells	T017	UMLS:C0597032
27601594	1201	1218	Immunosuppressive	T038	UMLS:C4048329
27601594	1219	1223	cell	T017	UMLS:C0007634
27601594	1261	1266	FoxP3	T103	UMLS:C4282118
27601594	1271	1275	PD-1	T103	UMLS:C2986635
27601594	1280	1285	cells	T017	UMLS:C0039198
27601594	1296	1314	regulatory T cells	T017	UMLS:C0039198
27601594	1317	1322	IDO-1	T103	UMLS:C3529891
27601594	1360	1371	macrophages	T017	UMLS:C0024432
27601594	1376	1387	tumor cells	T017	UMLS:C0597032
27601594	1390	1413	Hierarchical clustering	T062	UMLS:C1881045
27601594	1452	1455	TIL	T017	UMLS:C0079722
27601594	1463	1469	tumors	T038	UMLS:C0027651
27601594	1539	1542	TIL	T017	UMLS:C0079722
27601594	1654	1657	TIL	T017	UMLS:C0079722
27601594	1659	1667	negative	T033	UMLS:C0205160
27601594	1694	1702	negative	T033	UMLS:C0205160
27601594	1773	1785	chemotherapy	T058	UMLS:C0392920
27601594	1786	1789	TIL	T017	UMLS:C0079722
27601594	1877	1880	TIL	T017	UMLS:C0079722
27601594	1881	1890	responses	T038	UMLS:C0301909
27601594	1918	1947	immune-suppressive mechanisms	T038	UMLS:C1840264
27601594	2052	2065	immunotherapy	T058	UMLS:C0278348